All In Biotech

Drug Trial Radar · NCT07406633

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Kumquat Biosciences Inc.Industry
Sponsor type
Industry
First posted
Feb 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.

Conditions

  • GIST - Gastrointestinal Stromal Tumor
  • GIST
  • GIST Metastatic Cancer
  • Gastro Intestinal Stromal Tumour
  • Gastrointestinal Tumors

Interventions

  • KQB198Drug

    Oral KQB198

  • Imatinib (Gleevec)Drug

    Oral Imatinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: 30 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Hospitals

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • Northwell Health/R.J. Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UT MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.